Drug Profile
GEM ALS - GEMACBIO
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GEMACBIO
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in France
- 18 Jul 2005 Phase-I clinical trials in Amyotrophic lateral sclerosis in France (unspecified route)